Intestinal absorption of carbohydrates

"Intestinal absorption of carbohydrates" is **not a specific molecule or receptor**, but rather a physiological process involving the uptake of monosaccharides—primarily glucose, galactose, and fructose—across the epithelial cells lining the small intestine[1][2][3]. This process relies on several key **transport proteins**: - **SGLT1 (Sodium-glucose co-transporter 1):** Responsible for active transport of glucose and galactose into enterocytes via co-transport with sodium ions[2]. - **GLUT5:** Facilitates diffusion-mediated uptake of fructose into enterocytes[2]. - **GLUT2:** Transports all three monosaccharides from enterocytes into the bloodstream by facilitated diffusion[5]. Carbohydrate digestion begins in the mouth with salivary amylase breaking down starches; most enzymatic digestion occurs in the small intestine via pancreatic amylase and brush border enzymes. Only after being broken down to monosaccharides are carbohydrates absorbed. Indigestible fibers are not absorbed but pass to the colon for fermentation by gut bacteria[1][3]. Because "intestinal absorption of carbohydrates" refers to a complex physiological event rather than a single molecular target or druggable entity, it is not considered a canonical therapeutic target like an enzyme or receptor. However, drugs such as acarbose act indirectly on this process by inhibiting digestive enzymes upstream from absorption. In summary, this entry is *incorrect* as a molecular target because it describes an entire biological process rather than an individual protein or receptor that could be directly targeted by drugs. The actual targets relevant here would be specific transporters (e.g., SGLT1) or digestive enzymes involved in carbohydrate processing prior to absorption[2].

Inhibition of digestive enzymes (e.g., alpha-glucosidase inhibitors delay carbohydrate breakdown and thus absorption)